Genmab AS Capital Reinvestment Ratio
Genmab AS capital reinvestment ratio. Genmab AS (GMAB) has a Capital Reinvestment Ratio of 0.04x as of December 2025, meaning it reinvests 0% of its operating cash flow ($300.34 Million) in capital expenditures ($12.99 Million). See Genmab AS (GMAB) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Genmab AS (2007–2025)
Capital reinvestment ratio of Genmab AS from 2007 to 2025. This chart tracks Genmab AS's Capital Reinvestment Ratio across 15 annual periods. See GMAB FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
Genmab AS Capital Reinvestment Ratio by Year (2007–2025)
Genmab AS capital reinvestment ratio by year from 2007 to 2025. For the full cash flow conversion analysis, see GMAB operating cash flow.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.03x | $1.19 Billion | $37.03 Million | ▲ +29.6% |
| 2024 | 0.02x | $7.77 Billion | $187.00 Million | ▼ -52.8% |
| 2023 | 0.05x | $7.38 Billion | $376.00 Million | ▼ -37.1% |
| 2022 | 0.08x | $3.91 Billion | $317.00 Million | ▼ -28.4% |
| 2021 | 0.11x | $2.23 Billion | $252.00 Million | ▲ +137.0% |
| 2020 | 0.05x | $6.43 Billion | $307.00 Million | ▼ -43.0% |
| 2019 | 0.08x | $1.33 Billion | $111.00 Million | ▼ -82.2% |
| 2018 | 0.47x | $1.01 Billion | $477.37 Million | ▲ +744.5% |
| 2017 | 0.06x | $1.59 Billion | $88.51 Million | ▼ -44.9% |
| 2016 | 0.10x | $327.72 Million | $33.11 Million | ▼ -76.8% |
| 2015 | 0.43x | $311.45 Million | $135.39 Million | ▼ -23.6% |
| 2014 | 0.57x | $132.67 Million | $75.44 Million | ▲ +348.2% |
| 2012 | 0.13x | $70.92 Million | $9.00 Million | ▲ +236.5% |
| 2010 | 0.04x | $268.17 Million | $10.11 Million | ▲ +48.5% |
| 2007 | 0.03x | $505.90 Million | $12.84 Million | — |